Netherlands-based ScreenPoint Medical has acquired Biomediq A/S, the Danish developer of mammogram analysis technology, to advance the capabilities of its AI-powered Transpara: Breast AI screening tool.

Biomediq’s breast cancer risk analysis technology is centred around a mammographic texture risk biomarker model that recognises tissue heterogeneity, typically dubbed mammographic texture, that is associated with short-term and long-term breast cancer risk.

ScreenPoint gained clearance from the US Food and Drug Administration (FDA) in December 2024 for Transpara 2.1, the tool’s latest version.

The Transpara tool has been clinically proven to enhance 2D/3D mammography imaging analysis and improve radiologists’ ability to detect breast cancer earlier.

Based on additional training and insights gathered from users, the tool’s updated algorithm supports breast density (Breast Imaging Reporting and Data System [BIRADS] and volumetric) and temporal comparison options, meaning that suspicious areas from a current study can be analysed against up to three previous studies over six years – a capability ScreenPoint claims is the first of its kind on the market.

In a 2023 paper published in Radiology, the companies, who have worked together for around a decade, demonstrated that Transpara’s detection and density tools in combination with Biomediq’s texture model delivered improved breast cancer risk prediction.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Neither the monetary value nor the timeline for the deal’s completion was disclosed.

ScreenPoint Medical’s co-founder and chief scientific officer Nico Karssemeijer commented: “Risk-stratified screening has long been proposed to optimise screening for patients and better use resources.

“We are excited to add the Biomediq risk analysis technology to enhance the capabilities of Transpara to improve performance for mammography-based breast cancer risk assessment. This is a game-changing step in providing accurate and consistent breast cancer detection and care for all women.”

Biomediq co-founder Mads Nielsen added: “Joining our technologies to support radiology workflow and support care for women is an exciting fruit of this deep and complementary collaboration.”

A couple of developments occurred elsewhere in the breast cancer sector last November. GE HealthCare announced Pristina Via, a new mammography system intended to improve technologist workflow and patient-centred breast cancer care. During the same month, Densitas launched intelliRisk, a platform designed to provide a unified approach to patient and population health management across diagnostic, screening, prevention, and treatment pathways for breast cancer.